Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 4/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodofiltic Acid SCHEMBL4422557 | 1.00 | S1PR2 (0.50) | S1PR2S1PR1S1PR3S1PR4ALB | |
| Iodofiltic Acid SCHEMBL4422554 | 1.00 | S1PR2 (0.50) | S1PR2S1PR1S1PR3S1PR4ALB | |
| SCHEMBL5033209 | 1.00 | S1PR2 (0.50) | S1PR2S1PR1S1PR3S1PR4ALB | |
| SCHEMBL25954990 | 0.87 | MMP12 (0.45) | S1PR2S1PR1 | |
| SCHEMBL10925462 | 0.87 | MAPT (0.50) | S1PR2S1PR1S1PR3ALBALDH1A1 | |
| SCHEMBL10925065 | 0.87 | MAPT (0.54) | S1PR2S1PR1S1PR3ALB | |
| SCHEMBL5809402 | 0.87 | MAPT (0.54) | S1PR2S1PR1S1PR3ALB | |
| SCHEMBL14016007 | 0.86 | MAPT (0.56) | S1PR2S1PR1ALDH1A1TRPA1OXER1 | |
| SCHEMBL5074784 | 0.86 | MAPT (0.56) | S1PR2S1PR1ALDH1A1TRPA1OXER1 | |
| SCHEMBL23983038 | 0.85 | S1PR2 (0.50) | S1PR2S1PR1S1PR3S1PR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014512-A1 | COVALENT ORGANIC FRAMEWORKS FOR GAS CHROMATOGRAPHIC SEPARATIONS | UNIV NORTHWESTERN (US) | 2026-01-15 | — | — | US | claimed |
| WO-2024015937-A2 | COVALENT ORGANIC FRAMEWORKS FOR GAS CHROMATOGRAPHIC SEPARATIONS | NORTHWESTERN UNIVERSITY (US) | 2024-01-18 | — | — | WO | claimed |
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260014512-A1 | COVALENT ORGANIC FRAMEWORKS FOR GAS CHROMATOGRAPHIC SEPARATIONS | UNIV NORTHWESTERN (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2024015937-A2 | COVALENT ORGANIC FRAMEWORKS FOR GAS CHROMATOGRAPHIC SEPARATIONS | NORTHWESTERN UNIVERSITY (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-1067103-B1 | Process for producing halogenated benzene compound | SUMITOMO CHEMICAL CO (JP) | 2003-03-12 | — | — | EP | disclosed |
| EP-0832654-B1 | Radiation protection agents suitable for use with radiopharmaceuticals comprising reducible active ingredients | NIHON MEDIPHYSICS CO LTD (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-6307045-B1 | REACTING AN ORGANOMETALLIC COMPOUND WITH A HALIDE ION UNDER LIGHT IRRADIATION CONDITIONS IN THE PRESENCE OF A SEMICONDUCTOR CATALYST WITH A PHOTOCATALYTIC ACTIVITY. | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-10-23 | — | — | US | disclosed |
| US-6306603-B1 | NUCLEOTIDE SEQUENCES; PROBES; PRIMERS; DIAGNOSIS OF CARDIOMYOPATHY, JUVENILE SUDDEN DEATH, AND ACCIDENTS IN SURGICAL OPERATIONS | WAKUNAGA PHAEMACEUTICAL CO., LTD. (JP) | 2001-10-23 | — | — | US | disclosed |
| EP-1067103-A2 | Process for producing halogenated benzene compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-01-10 | — | — | EP | disclosed |
| US-6027710-A | PROTECTS THE ACTIVE INGREDIENT OF RADIOPHARMACEUTICALS AGAINST THE RADIOLYSIS CAUSED BY A REACTION OF THE ACTIVE INGREDIENT WITH WATER RADICALS FORMED BY RADIOLYSIS WITHOUT DECOMPOSING THE REACTIVE ACTIVE INGREDIENT (REDUCIBLE) | NIHON MEDI-PHYSISCS CO., LTD. (JP) | 2000-02-22 | — | — | US | disclosed |
| US-5993776-A | Radiopharmaceutical compositions that include an inclusion complex of a cyclodextrin and a radio-halogenated fatty acid | CIS BIO INTERNATIONAL (FR) | 1999-11-30 | — | — | US | disclosed |
| EP-0832654-A2 | Radiation-protecting agent | NIHON MEDI-PHYSICS Co., Ltd. (JP) | 1998-04-01 | — | — | EP | disclosed |
| US-5057301-A | MODIFIED CELLULAR SUBSTRATES USED AS LINKERS FOR INCREASED CELL RETENTION OF DIAGNOSTIC AND THERAPEUTIC AGENTS | NEORX CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | S1PR2 778/4885S1PR1 761/4885S1PR3 962/4885 |
| US-20260014512-A1 | COVALENT ORGANIC FRAMEWORKS FOR GAS CHROMATOGRAPHIC SEPARATIONS | TPR, F2, TERF2 | S1PR2 4224/4885S1PR1 4626/4885S1PR3 4725/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | S1PR2 1797/4885S1PR1 1705/4885S1PR3 2038/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | S1PR2 2946/4885S1PR1 2690/4885S1PR3 2517/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | S1PR2 1797/4885S1PR1 1705/4885S1PR3 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.